Health
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced that the Phase 1b clinical study of mazdutide injection (a glucagon-like peptide-1 [GLP-1] and glucagon [GCG] dual receptor agonist, R&D code: IBI362) in Chinese adolescents with obesity met its primary endpoint.
About this update from Innovent Biologics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior to those observed in the placebo group (BMI reduction: 1.73%; weight reduction: 1.42 kg; with nominal P values < 0.01). Furthermore, multiple metabolic parameters improved simultaneously.","length":438,"tagName":"p"}]},{"val":[{"type":"text","content":"Mazdutide demonstrated a favorable overall safety and tolerability profile. All enrolled subjects completed the protocol-specified visits. Throughout the study period, there were no serious adverse events (SAEs) reported in the mazdutide groups, and no subjects discontinued treatment due to adverse events (AEs).","length":313,"tagName":"p"}]},{"val":[{"type":"text","content":"there are currently no approved weight-loss medications specifically indicated for children and adolescents in China. A Phase 3 registrational clinical trial for adolescent obesity is scheduled to be initiated soon.","length":215,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":966,"olType":false},{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, Dec. 11, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced that the Phase 1b clinical study of mazdutide injection (a glucagon-like peptide-1 [GLP-1] and glucagon [GCG] dual receptor agonist, R&D code: IBI362) in Chinese adolescents with obesity met its primary endpoint.","length":586,"tagName":"p"},{"type":"text","content":"The global issue of childhood and adolescent obesity continues to escalate. According to a UNICEF report, the global obesity rate among children and adolescents aged 5–19 has risen from 3% to 9.4% since the year 2000. Obesity has now become a more prevalent form of malnutrition than underweight, affecting one in every ten school-aged children and adolescents (approximately 188 million individuals) and placing them at risk for severe health conditions [1].","length":459,"...